A comparative study of approaches used to improve solubility of roxithromycin

Powder Technology

Volumn 169, Issue 1, 2006, Pages 22-32

  Biradar, Shailesh V ^a   Patil, Arpana R ^a   Sudarsan, Guditi V ^a   Pokharkar, Varsha B ^a  

^a BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

Author keywords

Freeze drying; Homogenization; Roxithromycin; Spray drying; Ultra turrax

Indexed keywords

AMORPHOUS MATERIALS; DIFFERENTIAL SCANNING CALORIMETRY; DISSOLUTION; DRYING; HYDROPHILICITY; SOLUBILITY;

FREEZE DRYING; HOMOGENIZATION; ROXITHROMYCIN; SPRAY DRYING; ULTRA TURRAX;

DRUG PRODUCTS;

ROXITHROMYCIN;

AMORPHOUS MATERIALS; DIFFERENTIAL SCANNING CALORIMETRY; DISSOLUTION; DRUG PRODUCTS; DRYING; HYDROPHILICITY; SOLUBILITY;

ANTIMICROBIAL ACTIVITY; AQUEOUS SOLUTION; ARTICLE; CORRELATION ANALYSIS; DISSOLUTION; FREEZE DRYING; HYDROPHILICITY; PARTICLE SIZE; SPRAY DRYING;

EID: 33749263343     PISSN: 00325910     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.powtec.2006.07.016     Document Type: Article

References (23)

1. Lipinski C.A. Avoiding investment in doomed drugs, is poor solubility an industry wide problem?. Curr. Drug Discov. (2001) 17-19
2. Lipinski C.A. Poor aqueous solubility-an industry wide problem in drug discovery. Am. Pharm. Rev. 5 (2002) 82-85
3. Rasenack N., Hartenhauer H., and Muller B.W. Microcrystals for dissolution rate enhancement of poorly-water soluble drugs. Int. J. Pharm. 254 2 (2003) 137-145
4. Liversidge E., Liversidge G.G., and Cooper E.R. Nanosizing: a formulation approach for poorly water-soluble compounds. Eur. J. Pharm. Sci. 18 (2003) 113-120
5. Hancock B.C., and Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J. Pharm. Sci. 86 (1997) 1-12
6. Yagamuch T., Nishimura M., Okamoto R., Takeuchi T., and Yamamoto K. Physico-chemical stability of glassy 16-membered macrolide compounds. Chem. Pharm. Bull. 41 (1993) 1812-1816
7. Bolhuis G.K., Zuurman K., and Wierik G.H.P. Improvement of dissolution of poorly soluble drugs by solid deposition on a super disintegrant. II. The choice super disintegrant and effect of granulation. Eur. J. Pharm. Sci. 5 (1996) 63-69
8. Okonogi S., Yonemochi E., Oguchi Y., Puttipipatkhachorn S., and Yamamoto K. Enhanced dissolution of ursodeoxycholic acid from the solid dispersion. Drug Dev. Ind. Pharm. 23 (1997) 1-7
9. Yu L. Amorphous pharmaceutical solids; preparation, characterization and stabilization. Adv. Drug Del. Rev. 48 (2001) 27-42
10. Broman E., Khoo C., and Taylor L.S. A comparison of alternative polymer excipients and processing methods for making solid dispersions of a poorly water soluble drug. Int. J. Pharm. 222 (2001) 139-151
11. R.H. Muller, R. Becker, B. Kruss, K. Peters, Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution, US Patent 5,858,410, January 12, 1999.
12. Yonemochi E., Kitahara S., Maeda S., Yamamura T., Oguchi S., and Yamamoto K. Physicochemical properties of amorphous clarithromycin obtained by grinding and spray drying. Eur. J. Pharm. Sci. 7 (1999) 331-338
13. Koester L.S., Mayorga P., and Bassani V.L. Carbamazepine/βCD/HPMC solid dispersion. I. Influence of the spray drying process and β/CD/HPMC on the drug dissolution profile. Drug Dev. Ind. Pharm. 29 2 (2003) 145-154
14. Corrigan D.O., Corrigan O.I., and Healy A.M. The effect of spray drying solutions of bendroflumethiazide/polyethylene glycol on the physiological properties of resultant materials. Int. J. Pharm. 262 (2003) 125-137
15. Krisch L., Zhnag S., Mvangsiri W., Redmon M., Luner P., and Wurster D. Development of a lyophilized formulation for (R, R)-Formoterol (L)-Tartarate. Drug Dev. Ind. Pharm. 27 1 (2001) 89-96
16. Conte U., Conti B., Giunchedi P., and Maggi L. Spary dried polylactide microsphere preparation: influence of the technological parameters. Drug Dev. Ind. Pharm. 20 3 (1994) 235-258
17. Bitz C., and Doelker E. Influence of the preparation method on residual solvents in biodegradable microspheres. Int. J. Pharm. 131 (1996) 171-181
18. Laccase F.X., Hilden P., and McMullen. Surface and morphology of spray dried peglyated PLA-microspheres. Int. J. Pharm. 174 (1998) 101-109
19. Control Of Volatile Organic Emissions From Manufacture of Synthesized Pharmaceutical Products, EPA-450/2-78-029, U. S. Environmental Protection Agency, Research Triangle Park, NC, December 1978.
20. International Conference on Harmonization, Impurities, Guidelines for Residual Solvent, 1997. Q3C. Federal Register. 62, p. 67377.
21. Uip D.E., and Neto V.A. Roxithromycin treatment for diarrhea caused by Cryptosporidium parvum in patients with AIDS. J. Antimicrob. Chemother. 41 Suppl. B (1998) 93-97
22. Muller R.H., Jacobs C., and Kayser O. Nanosuspension as particulate drug formulations in therapy rationale for development and what we can except for the future. Adv. Drug Deliv. Rev. 47 (2001) 3-19
23. Nash R.A. In: Herbert A., Liberman, Martin M., Ringer, and Glibert S. (Eds). Pharmaceutical suspension. 2nd ed. Pharmaceutical Dosage Forms: Disperse Systems vol. 2 (1996), Marcel Dekker, Inc, New York 1-46